Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
NCT ID: NCT06852950
Last Updated: 2025-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2025-03-09
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
NCT06752928
Dexcom G6 Observational Study
NCT03832907
Dexcom G6 Intervention Study
NCT03877068
Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations
NCT06939413
Dexcom Continuous Glucose Monitoring in Long-term Care
NCT04818242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Libre 3 Plus Continuous Glucose Monitor
Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
Libre 3 Plus Continuous Glucose Monitor
Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
Dexcom G7 Continuous Glucose Monitor
Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
Dexcom G7 Continuous Glucose Monitor
Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Libre 3 Plus Continuous Glucose Monitor
Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
Dexcom G7 Continuous Glucose Monitor
Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give informed consent
* Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
* POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
* Need glucose readings greater than or equal to one time per day
* Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone
Exclusion Criteria
* Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
* Received chemotherapy during current hospitalization
* Planning on major surgery within 10-15 days
* Hemodialysis or peritoneal dialysis
* Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
* Vitamin C use of more than 500 milligrams per day
* Hydroxyurea use
* Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
* Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
* Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
* Skin allergy to adhesives
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanderbilt University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angel Morvant
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
242071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.